ClinicalTrials.gg
Not yet recruitingNCT07380308MYODiaphUpdated Feb 2, 2026

" Development of Primary Cultures of Diaphragmatic Myoblasts for Basic Research Purposes "

An observational study in Endometriosis, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-02.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Endometriosis by Assistance Publique - Hôpitaux de Paris — 6 open to participants now, 7 under way, none of them phase 3. Endometriosis · Assistance Publique - Hôpitaux de Paris.

Started
2026
with 2 others
Observational
6 of 12
3 open now
Registered
12th of 12
by date

Among the 12 studies in Endometriosis by Assistance Publique - Hôpitaux de Paris, this one is one of 3 that started in 2026, is one of 6 observational ones, and was the 12th registered.

Endometriosis

924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.

Browse Endometriosis studies →

Open to participants now

6 of the 12 studies in Endometriosis by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Endometriosis by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Neuromuscular diseases (NMDs) affecting motor neurons (MN) induce progressive muscle denervation, and become fatal when respiratory muscles e.g. the diaphragm are affected and can no longer contract. In some cases, such as Charcot's disease (Amyotrophic lateral sclerosis-ALS), there is no cure and patients die due to respiratory failure few years after diagnosis. Investigations on NMD-induced alterations of respiratory muscles in humans are limited notably by the absence of available in vitro model based on cell cultures of diaphragm-derived myoblasts. Yet, this cell tool is likely to help in developing original therapies to limit diaphragm muscle atrophy and dysfunction in NMD. To date, only cell cultures of human myoblasts obtained from limb muscles are available, making difficult to transpose results to the diaphragm.

Thus, in the present project, we propose to :

  1. originally develop primary cultures of myoblasts from human diaphragm, obtained from surgical resection of diaphragmatic endometriosis,
  2. characterize them in terms of differentiation status (Histology, IF), metabolism (Metabolomics by NMR, cell respiration), and gene expression (RNASeq), in comparison to primary myoblasts cultures derived from the deltoid already available in the team.

This project will provide an original new tool and important data on the specificity of diaphragm-derived myoblasts, compared to limb muscle-derived myoblasts with the long-term perspective of opening new therapeutical pathways for patients with severe NMDs.

Read the detailed description

Neuromuscular diseases (NMDs) affecting motor neurons (MN) induce progressive muscle denervation, and become fatal when respiratory muscles e.g. the diaphragm are affected and can no longer contract. In some cases, such as Charcot's disease (Amyotrophic lateral sclerosis-ALS), there is no cure and patients die due to respiratory failure few years after diagnosis. Investigations on NMD-induced alterations of respiratory muscles in humans are limited notably by the absence of available in vitro model based on cell cultures of diaphragm-derived myoblasts. Yet, this cell tool is likely to help in developing original therapies to limit diaphragm muscle atrophy and dysfunction in NMD. To date, only cell cultures of human myoblasts obtained from limb muscles are available, making difficult to transpose results to the diaphragm.

Thus, in the present project, we propose to :

  1. originally develop primary cultures of myoblasts from human diaphragm, obtained from surgical resection of diaphragmatic endometriosis,
  2. characterize them in terms of differentiation status (Histology, IF), metabolism (Metabolomics by NMR, cell respiration), and gene expression (RNASeq), in comparison to primary myoblasts cultures derived from the deltoid already available in the team.

This project will provide an original new tool and important data on the specificity of diaphragm-derived myoblasts, compared to limb muscle-derived myoblasts with the long-term perspective of opening new therapeutical pathways for patients with severe NMDs.

03

Conditions studied

  • Endometriosis

Browse trials for

Keywords

  • Diaphragmatic endometriosis
  • Surgical nodules resection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with diaphragmatic endometriosis requiring surgical nodules resection in the diaphragm.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • diaphragmatic endometriosis requiring surgical resection of the nodules in the diaphragm.
  • Collection of non-opposition

Exclusion criteria

Exclusion Criteria

  • Inability to speak and/or read French
  • Patients under tutor or curatorship
  • Protected adults
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Patients

    Patients with endometriosis requiring surgical nodules resection in the diaphragm.

    Other: During the surgery planned as part of the routine care of the patient, a part of the tissue sample will be saved in order to carry out the analysis planned for the research.

Interventions

  • OtherDuring the surgery planned as part of the routine care of the patient, a part of the tissue sample will be saved in order to carry out the analysis planned for the research.

    During the surgery planned as part of the routine care of the patient, a part of the tissue sample will be saved in order to carry out the analysis planned for the research.

06

What researchers measure

Primary outcomes

  1. Molecular characteristics

    The primary endpoint will be the identification of molecular and cellular signatures specific of the diaphragm as compared with human deltoid muscle cultures, notably based on the study of : * differentiation, by studying the course of myoblast differentiation and fusion in polynucleated myotubes (IF Desmin, Slow and fast Myosin Heavy Chain), * energy metabolism (extra- and intra-cellular metabolomics by NMR, cell respiration by the Seahorse technology), * gene regulation, by analysing the transcriptomic signature (RNAseq).

    Time frame: Inclusion

  2. Cellular characteristics

    The primary endpoint will be the identification of molecular and cellular signatures specific of the diaphragm as compared with human deltoid muscle cultures, notably based on the study of : * differentiation, by studying the course of myoblast differentiation and fusion in polynucleated myotubes (IF Desmin, Slow and fast Myosin Heavy Chain), * energy metabolism (extra- and intra-cellular metabolomics by NMR, cell respiration by the Seahorse technology), * gene regulation, by analysing the transcriptomic signature (RNAseq).

    Time frame: Inclusion

Secondary outcomes

  1. Presence of diaphragm-derived myoblasts

    The secondary endpoint will be to build a library of molecular and cellular signatures for the major respiratory muscle i.e. the diaphragm in human. Decisive differences between cellular and molecular signatures across muscles (Diaphragm and Deltoid) will be analysed by principal component analysis.

    Time frame: Inclusion

07

Study locations

1 site
  • Department of Thoracic Surgery - Cochin Hospital
    Paris, IDF 75014, France
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Apr 2026, 2 months later.

Of 158 non-industry observational studies under Endometriosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 2 months is below that.

Counting every sponsor, half of 185 studies reached it within 30 months; a quarter within 14 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2026
First posted
Feb 2, 2026
StartEst.
Feb 1, 2026
Primary completionEst.
Apr 1, 2026
CompletionEst.
May 1, 2026
Last update
Feb 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07380308
Collaborators
URC-CIC Paris Descartes Necker Cochin, UMR INSERM 1124
Responsible party
Sponsor
First posted
Feb 2, 2026
Start date
Feb 1, 2026 (estimated)
Primary completion
Apr 1, 2026 (estimated)
Completion
May 1, 2026 (estimated)
Last update
Feb 2, 2026

Study contacts

Christelle NGUYEN, MD, PHD
Contact
christelle.nguyen2@aphp.fr
00 33 1 58 41 29 45
Marie BENHAMMANI-GODARD
Contact
marie.godard@aphp.fr
0033158411190
Christelle NGUYEN, MD, PHD
study director · Physical Medicine and Rehabilitation Department - Cochin hospital
Marco ALIFANO, MD, PHD
principal investigator · Department of Thoracic Surgery - Cochin Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion